Source link : https://www.newshealth.biz/health-news/fda-expands-dupilumab-for-eoe-to-younger-children/
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent, Regeneron/Sanofi) for the treatment of eosinophilic esophagitis (EoE) in children aged 1-11 years and weighing ≥ 15 kg. It is the first and only medicine approved to treat these patients. The FDA previously approved the drug for EoE in persons aged 12 years or […]
Author : News Health
Publish date : 2024-01-25 22:16:27
Copyright for syndicated content belongs to the linked Source.